Home › Research › Drug development
Alzheimer's disease and its treatment-yesterday, today, and tomorrow
Kim AY, Al Jerdi S, MacDonald R, Triggle CR.. Frontiers in pharmacology, 2024-05-24
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alois Alzheimer described the first patient with Alzheimer's disease (AD) in 1907 and today AD is the most frequently diagnosed of dementias. AD is a multi-factorial neurodegenerative disorder with familial, life style and comorbidity influences impacting a global population of more than 47 million with a projected escalation by 2050 to exceed 130 million. In the USA the AD demographic encompasses approximately six million individuals, expected to increase to surpass 13 million by 2050, and the antecedent phase of AD, recognized as mild cognitive impairment (MCI), involves nearly 12 million individuals.
What this study adds
Evidence grade: Low
This is a narrative review. This narrative review describes Alzheimer's disease as a multi-factorial disorder influenced by familial, lifestyle and comorbidity factors, with a global population projected to exceed 130 million by 2050. It provides background on the scale of the disease rather than reporting a new treatment, cure or prevention result.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kim, A. Y., Al Jerdi, S., MacDonald, R., & Triggle, C. R. (2024). Alzheimer's disease and its treatment-yesterday, today, and tomorrow. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2024.1399121
Vancouver
Kim AY, Al Jerdi S, MacDonald R, Triggle CR. Alzheimer's disease and its treatment-yesterday, today, and tomorrow. Frontiers in pharmacology. 2024. doi:10.3389/fphar.2024.1399121. PMID: 38868666.
BibTeX
@article{kim2024-38868666,
author = {Kim, A. Y. and Al Jerdi, S. and MacDonald, R. and Triggle, C. R.},
title = {{Alzheimer's disease and its treatment-yesterday, today, and tomorrow}},
journal = {Frontiers in pharmacology},
year = {2024},
doi = {10.3389/fphar.2024.1399121},
pmid = {38868666},
url = {https://doi.org/10.3389/fphar.2024.1399121}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- AD is a multi-factorial neurodegenerative disorder with familial, life style and comorbidity influences impacting a global population of more than 47 million with a projected escalation by 2050 to exceed 130 million.
- In the USA the AD demographic encompasses approximately six million individuals, expected to increase to surpass 13 million by 2050, and the antecedent phase of AD, recognized as mild cognitive impairment (MCI), involves nearly 12 million individuals.
- The economic outlay for the management of AD and AD-related cognitive decline is estimated at approximately 355 billion USD.
- In addition, the intensifying prevalence of AD cases in countries with modest to intermediate income countries further enhances the urgency for more therapeutically and cost-effective treatments and for improving the quality of life for patients and their families.
Why it matters
This narrative review describes Alzheimer's disease as a multi-factorial disorder influenced by familial, lifestyle and comorbidity factors, with a global population projected to exceed 130 million by 2050. It provides background on the scale of the disease rather than reporting a new treatment, cure or prevention result.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designnarrative review
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in pharmacology) |
| Journal's citation record | 2 / 4 | Frontiers in Pharmacology: journal h-index 242 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 83 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 20.8 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 19.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 83 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Chris R. Triggle: h-index 56 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Weill Cornell Medicine: institution h-index 1,163 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38868666) |
| Free to read | 2 / 2 | Free to read |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fphar.2024.1399121
- PubMed: 38868666
- Original source →
- Free full text: Frontiers in Pharmacology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 79.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Drug development from nearby years
Also in Drug development
124 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.